CLAIMS

1. A bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic immunoglobulin single variable domain (ISV) construct with an ISV at its C-terminal end, for use in a method of therapy, wherein said ISV construct has the sequence VTVSS(X)n at its C-terminus, wherein n = 1 to 10 and X represents amino acid residues that are independently chosen from naturally occurring amino acids.

2. The bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct for use according to claim 1, wherein n = 1, 2, 3, 4 or 5.

3. The bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct for use according to claims 1 or claim 2, wherein each X is independently chosen from alanine, glycine, valine, leucine or isoleucine.

4. The bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct for use according to any one of claims 1 to 3, wherein
    a) X is Ala and n is 1, 2 or 3; or
    b) X is Gly and n is 1, 2 or 3.

5. The bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct for use according to any one of claims 1 to 4, wherein X is Ala and n is 1.

6. The bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct for use according to any one of claims 1 to 5, wherein the ISV at the C-terminal end has been modified by replacing the amino acid residue alanine at position 14 according to Kabat numbering, with proline.

7. The bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct for use according to claim 6, wherein the ISV at the C-terminal end has

been modified by introducing one or more amino acid substitutions, additions in the C-terminal end comprising the amino acid sequence VTVSS (SEQ ID NO: 33).

8. The bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct for use according to any one of claims 1 to 7, wherein each ISV is a humanized VHH or a camelized VH, such as a camelized human VH.

9. The bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct for use according to any one of claims 1 to 8, that comprise a serum albumin-binding peptide or binding domain.

10. A pharmaceutical composition that comprises a bivalent, multivalent, bispecific, multispecific, biparatopic or multiparatopic ISV construct with an ISV at its C-terminal end wherein said ISV construct has the sequence VTVSS(X)n at its C-terminus, wherein n = 1 to 10 and X represents amino acid residues that are independently chosen from naturally occurring amino acids, and further comprising at least one suitable carrier, diluent or excipient.